Computational study on the binding and unbinding mechanism of HCV NS5B with the inhibitor GS-461203 and substrate using conventional and steered molecular …

D Pan, Y Niu, L Ning, Y Zhang, H Liu, X Yao - Chemometrics and Intelligent …, 2016 - Elsevier
The active metabolite GS-461203 of hepatitis C virus (HCV) non-structural protein 5B
(NS5B) inhibitor sofosbuvir can stall RNA synthesis or replication by competitively inhibiting …

Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro

C Alotte, A Martin, SA Caldarelli, A Di Giorgio… - Antiviral research, 2008 - Elsevier
The internal ribosome entry site (IRES) of hepatitis C virus (HCV) which governs the
initiation of protein synthesis from viral RNA represents an ideal target for antisense …

Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development

C Welsch - Drug Discovery Today: Technologies, 2014 - Elsevier
The approval of direct-acting antiviral agents (DAAs) has marked a pivotal change in the
treatment landscape of chronic hepatitis C. As for DAAs targeting other viral diseases, there …

Evaluation systems for anti-HCV drugs

K Moriishi, Y Matsuura - Advanced drug delivery reviews, 2007 - Elsevier
Development of therapeutics for chronic hepatitis C has been hampered by the lack of an
efficient cell culture system and a small animal model for the hepatitis C virus (HCV). An …

Synthesis, in vitro and in silico NS5B polymerase inhibitory activity of benzimidazole derivatives

VM Patil, G KR, M Chudayeu… - Medicinal …, 2012 - ingentaconnect.com
Hepatitis C virus (HCV) NS5B polymerase is the key replicating protein of the virus and thus
an attractive target for drug development. Here we report on the synthesis and biological …

Transmission genetics of drug-resistant hepatitis C virus

N van Buuren, TL Tellinghuisen, CD Richardson… - Elife, 2018 - elifesciences.org
Antiviral development is plagued by drug resistance and genetic barriers to resistance are
needed. For HIV and hepatitis C virus (HCV), combination therapy has proved life-saving …

Phosphoramidate dinucleosides as hepatitis C virus polymerase inhibitors

I Zlatev, H Dutartre, I Barvik, J Neyts… - Journal of medicinal …, 2008 - ACS Publications
GC dinucleosides exhibiting a phosphoramidate internucleosidic linkage with neutral,
amphiphile, positively or negatively charged side chains were synthesized. Their potential …

Resistance mechanisms in HCV: from evolution to intervention

AY Kim, J Timm - Expert Review of Anti-infective Therapy, 2008 - Taylor & Francis
Recent advances in our understanding of the HCV life cycle and the functions of virally
encoded proteins enabled the development of specifically targeted antiviral therapies for …

Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, Pakistan

M Ali, IU Rehman, M Idrees - Virus Genes, 2014 - Springer
Mutations in NS5B gene of Hepatitis C virus (HCV) have been reported in patients
undergoing antiviral therapy. In the present study, we report emerging clade of HCV-3a in …

Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women

PD Dryer, BN Limketkai, CM Martin… - Journal of …, 2009 - academic.oup.com
Abstract Objectives Hepatitis C virus (HCV) non-nucleoside inhibitors (NNIs) target the viral
RNA-dependent RNA polymerase encoded by the NS5B gene. Several NNIs share a similar …